5. 進行性核上性麻痺 Progressive supranuclear palsy Clinical trials / Disease details

臨床試験数 : 95 / 薬物数 : 119 - (DrugBank : 40) / 標的遺伝子数 : 65 - 標的パスウェイ数 : 108

3 trials found

diseases per page:

Showing 1 to 3 of 3 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02839642 (ClinicalTrials.gov)	July 26, 2016	30/6/2016	Efficacy of RIVAstigmineon Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear P ...	RIVA-PSP: Efficacy of Rivastigmineon Motor, Cognitive and Behavioural Impairment in Progressive Supr ...	Progressive Supranuclear Palsy (PSP)	Drug: Rivastigmine;Drug: Placebo	Assistance Publique Hopitaux De Marseille	NULL	Recruiting	41 Years	80 Years	All	106	Phase 3	France
2	NCT00522015 (ClinicalTrials.gov)	February 2008	27/8/2007	Efficacy Study for Treatment of Dementia in Progressive Supranuclear Palsy	Rivastigmine(Exelon®) for Treatment of Dementia in Patient With Progressive Supranuclear Paresis Ope ...	Progressive Supranuclear Palsy;Dementia	Drug: rivastigmine	University Hospital Tuebingen	NULL	Recruiting	50 Years	N/A	Both	20	Phase 2	Germany
3	EUCTR2006-006166-42-DE (EUCTR)	17/07/2007	02/01/2007	Exelon bei dementiellem Syndrom bei Patienten mit Progressiver Supranukleärer Parese -offene, prospe ...	Exelon bei dementiellem Syndrom bei Patienten mit Progressiver Supranukleärer Parese -offene, prospe ...	Progressive supranuclear palsy (PSP) is a neurodegenerative disorder with hardly any therapeutical o ...	Trade Name: Exelon 1,5 mg Hartkapseln INN or Proposed INN: RIVASTIGMINE Trade Name: Exelon 3,0 mg Hart ...	University of Tuebingen	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes		Phase 2	Germany

First Previous1Next Last